FDA and EMA Guidance on Post-Approval Shelf Life Changes
Once a drug product is approved, changes to its shelf life—whether an extension or reduction—require careful navigation through post-approval regulatory procedures. Among the most influential authorities, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have well-defined, but distinct, guidelines. This article unpacks their expectations for documentation, submission types, stability data,…
Read More “FDA and EMA Guidance on Post-Approval Shelf Life Changes” »